VivoSeq
Oncology

High Risk Smoldering Multiple Myeloma (HR-SMM)

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

High Risk Smoldering Multiple Myeloma (HR-SMM) is an early-stage landscape with 2 programs across 2 companies. The most active players are Regeneron, Johnson & Johnson. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Linvoseltamab

Regeneron

Daratumumab

Johnson & Johnson

Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Recruiting·Regeneron logoRegeneron·Phase 3·NCT07393282·270 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)